CClinicalTrials.gg
CompletedNCT04135066WEBRAINUpdated Jun 13, 2025

Westlake Nutrition and Brain Health Study

An interventional study of Refine grain breakfast and Whole grain breakfast in Aging, sponsored by Westlake University. Completed at 1 site in China. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Westlake University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
1,425
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

The Westlake Nutrition and Brain Study (WEBRAIN), a sub-study of the Guangzhou Nutrition and Health Study, is a prospective cohort study of residents in Guangzhou city. WEBRAIN aims to explore the links between diet, gut microbiome, and brain health in elderly individuals through comprehensive phenotyping, including continuous blood glucose monitoring for standardized test meals, objective physical activity measurement, and brain magnetic resonance imaging.

Read the detailed description

The gut-brain axis is implicated in neurodegenerative diseases through various mechanisms, with diet and nutrition linked to both gut and brain health. However, most evidence comes from animal models or small-scale human studies.

The Westlake Nutrition and Brain Study (WEBRAIN) aims to investigate the relationships among diet, gut microbiome, and brain structure and function in a large human cohort through comprehensive phenotyping: 1) objective physical activity measurement using accelerometers over two weeks; 2) continuous blood glucose monitoring for two weeks, including two standardized test meals, alongside traditional dietary assessment via Food Frequency Questionnaires (FFQ) and 24-hour recalls; 3) assessment of cognitive function and brain imaging using the Addenbrooke's Cognitive Examination-Revised (ACE-R) and brain MRI; and 4) gut microbiome profiling analysis using sequencing techniques.

02

Conditions studied

  • Aging

Keywords

  • Brain structure and function
  • Nutrition
  • Microbiome
  • Continuous blood glucose monitoring
03

In context

Lead sponsor

Westlake University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Participants from the Guangzhou Nutrition and Health Study, lived in Guangzhou, China, and aged 45 years or older;

Exclusion criteria

Exclusion Criteria:

Metal implants and other contraindications for magnetic resonance imaging scanning

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
1,425 participants (actual)

Study arms

  • Other
    Group A (RG-WG-OGTT)

    Starting on Day 1 with a continuous glucose monitoring (CGM) sensor, refined grain breakfasts (RG) are provided on Days 3 and 4, whole grain breakfasts (WG) are provided on Days 6 and 7, and an oral glucose tolerance test (OGTT) is conducted on Day 9. On other days during CGM activation, breakfast is unrestricted.

    Other: Refine grain breakfast · Other: Whole grain breakfast · Other: Oral Glucose Tolerance test (75g 2-hour)

  • Other
    Group B (WG-OGTT-RG)

    Starting on Day 1 with a continuous glucose monitoring (CGM) sensor, whole grain breakfasts (WG) are provided on Days 3 and 4, an oral glucose tolerance test (OGTT) is conducted on Day 6, and refined grain breakfasts (RG) are provided on Days 8 and 9. On other days during CGM activation, breakfast is unrestricted.

    Other: Refine grain breakfast · Other: Whole grain breakfast · Other: Oral Glucose Tolerance test (75g 2-hour)

  • Other
    Group C (OGTT-RG-WG)

    Starting on Day 1 with a continuous glucose monitoring (CGM) sensor, an oral glucose tolerance test (OGTT) is conducted on Day 3, refined grain breakfasts (RG) are provided on Days 5 and 6, and whole grain breakfasts (WG) are provided on Days 8 and 9. On other days during CGM activation, breakfast is unrestricted.

    Other: Refine grain breakfast · Other: Whole grain breakfast · Other: Oral Glucose Tolerance test (75g 2-hour)

Interventions

  • OtherRefine grain breakfast

    After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.

    Also known as: Breakfast A

  • OtherWhole grain breakfast

    After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.

    Also known as: Breakfast B

  • OtherOral Glucose Tolerance test (75g 2-hour)

    75 g pure glucose with 300 mL water per time per person is applied. In the following 3 hours, participants are advised to rest in a seated position, avoiding unnecessary walking or exercise. Energy-giving food items were still prohibited within this interval.

06

What researchers measure

Primary outcomes

  1. Continuous blood glucose profile over 2 weeks

    Glucose levels were measured by a continuous glucose monitor over 2 weeks.

    Time frame: at enrollment

  2. Brain images

    Brain structure and function were measured by brain magnetic resonance imaging (MRI).

    Time frame: at enrollment

Secondary outcomes

  1. Cognitive scores

    Cognitive function was measured by the Addenbrooke's Cognitive Examination-Revised (ACE-R). The original 26 components were combined to produce five subscores, 100 in total. The cutoff for dementia is 82-88/100.

    Time frame: at enrollment

  2. Incidence of Alzheimer's disease (AD)

    New cases of AD will be diagnosed by neurological clinician according to the Chinese guideline for the diagnosis and treatment of Alzheimer's disease dementia(2020).

    Time frame: 6 and 10 years after enrollment

  3. Structure of gut microbiome profile

    Gut microbiome profile for each participant is measured by metagenome and ITS2 sequencing.

    Time frame: At enrollment

07

Study locations

1 site
  • Sun Yat-sen University
    Guangzhou, Guangdong 510275, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04135066
Lead sponsor
Westlake University
Collaborators
Sun Yat-sen University
Responsible party
Sponsor
First posted
Oct 22, 2019
Start date
Nov 1, 2020
Primary completion
Apr 28, 2025
Completion
May 21, 2025
Last update
Jun 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion